Genetic Testing

Applied DNA Awarded Contract by HDT Bio For Rapid Vaccine Development ProgramApplied DNA Awarded Contract by HDT Bio For Rapid Vaccine Development Program

Applied DNA Awarded Contract by HDT Bio For Rapid Vaccine Development Program

Award Seeks to Demonstrate Feasibility of Manufacturing mRNA Vaccines in Only 7 Days  STONY BROOK, NY / ACCESSWIRE / April…

1 year ago
Applied DNA Announces 1-For-20 Reverse Stock SplitApplied DNA Announces 1-For-20 Reverse Stock Split

Applied DNA Announces 1-For-20 Reverse Stock Split

STONY BROOK, NY / ACCESSWIRE / April 22, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the Company),…

1 year ago
Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health MonitorNearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor

Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor

80% of people diagnosed with anxiety, depression report losing years or decades of timeSALT LAKE CITY, April 17, 2024 (GLOBE…

1 year ago
GeneType Clinicians’ Adoption Growing – Sales up 5-Fold Year on YearGeneType Clinicians’ Adoption Growing – Sales up 5-Fold Year on Year

GeneType Clinicians’ Adoption Growing – Sales up 5-Fold Year on Year

MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader…

1 year ago
Multicancer Screening Market Projected to Reach $2.72 billion by 2030 – Exclusive Report by 360iResearchMulticancer Screening Market Projected to Reach $2.72 billion by 2030 – Exclusive Report by 360iResearch

Multicancer Screening Market Projected to Reach $2.72 billion by 2030 – Exclusive Report by 360iResearch

PUNE, India, April 15, 2024 /PRNewswire/ -- The report titled "Multicancer Screening Market by Product (AI and Machine Learning-Based Platforms,…

1 year ago
CancerIQ CEO Feyi Ayodele Named to Modern Healthcare’s 2024 Innovators ListCancerIQ CEO Feyi Ayodele Named to Modern Healthcare’s 2024 Innovators List

CancerIQ CEO Feyi Ayodele Named to Modern Healthcare’s 2024 Innovators List

CHICAGO--(BUSINESS WIRE)--#aheadofcancer--CancerIQ is proud to announce that co-founder and CEO Feyi Ayodele was recognized by Modern Healthcare as one of…

1 year ago
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight TestingMyriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing

Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing

Fewer patients were prescribed medications with gene-drug interactions after taking the GeneSight testSALT LAKE CITY, April 09, 2024 (GLOBE NEWSWIRE)…

1 year ago
EVENT – Empowering Women Through Knowledge; Humanise Health & GeneType Launch “Know Your Risk”EVENT – Empowering Women Through Knowledge; Humanise Health & GeneType Launch “Know Your Risk”

EVENT – Empowering Women Through Knowledge; Humanise Health & GeneType Launch “Know Your Risk”

MELBOURNE, Australia, April 08, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader…

1 year ago
Shifa Health Marks 21 Years of Transformative Mental Health CareShifa Health Marks 21 Years of Transformative Mental Health Care

Shifa Health Marks 21 Years of Transformative Mental Health Care

A Celebration of Innovation, Compassion, and Community EngagementEVERETT, WA / ACCESSWIRE / April 3, 2024 / Shifa Health, a leading…

1 year ago
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific AgonistRhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

-- Three-part study to evaluate safety, tolerability and pharmacokinetics now underway -- -- RM-718 showed potential to reduce body weight…

1 year ago